口服特比萘芬或灰黄霉素治疗皮肤癣菌感染时实验室检查结果监测的效用
这项回顾性研究评估了2006年1月1日至2016年12月31日期间在一家美国中西部医疗系统内服用特比萘芬或灰黄霉素治疗皮肤癣菌感染的成人和儿童,发现实验室检查结果异常率低,且与基线异常率相当,大多数异常为低级别且无需后续评估或停药。作者认为,对于无基础肝脏或血液疾病的患者,常规间隔实验室监测似乎没有必要。
要点
- 服用特比萘芬或灰黄霉素的患者实验室检查结果异常率低,且与基线异常率相当。
- 大多数实验室检查结果异常为低级别(212例,93.4%为1级),无需后续评估或停药(15051次,99.9%)。
- 作者认为,对于无基础肝脏或血液疾病的成人和儿童,常规间隔实验室监测似乎没有必要。
核心结论
- 服用特比萘芬或灰黄霉素的成人和儿童中,丙氨酸氨基转移酶升高、天冬氨酸氨基转移酶升高、贫血、淋巴细胞减少和中性粒细胞减少的发生率低,且与基线异常率相当。
- 对于无基础肝脏或血液疾病的成人和儿童,常规间隔实验室检查结果监测似乎没有必要。
- 放弃频繁的实验室监测可以减少不必要的医疗支出,减轻患者因抽血产生的心理焦虑,并允许扩大这些有效口服药物的使用。
研究设计与样本
- 这项回顾性研究评估了2006年1月1日至2016年12月31日期间在一家美国中西部医疗系统内服用特比萘芬或灰黄霉素治疗皮肤癣菌感染的成人和儿童。
- 排除标准为既往诊断为肝脏或血液疾病以及既往或同时使用口服酮康唑、两性霉素B或伊曲康唑。
- 研究纳入4985例患者的实验室数据(平均[标准差]年龄,42.8[20.3]岁;2288例[45.9%]女性),涉及4309个特比萘芬疗程、634个灰黄霉素微粒疗程和159个灰黄霉素超微粒疗程。
主要发现
- 服用特比萘芬或灰黄霉素的患者实验室检查结果异常率低。
- 实验室检查结果异常发生时,大多数为低级别(212例[93.4%]为1级),且无需后续实验室检查结果评估或停药(15051次[99.9%])。
- 丙氨酸氨基转移酶升高检出率低,与基线检出率相当(特比萘芬:61例[3.5%] vs 基线95例[3.6%];灰黄霉素微粒:2例[2.1%] vs 基线3例[3.7%];灰黄霉素超微粒:0例 vs 基线2例[5.0%])。
- 天冬氨酸氨基转移酶升高、贫血、淋巴细胞减少和中性粒细胞减少的发生率也低,与基线率相当。
临床怎么用
- 作者认为,对于无基础肝脏或血液疾病、服用特比萘芬或灰黄霉素治疗皮肤癣菌感染的成人和儿童,常规间隔实验室检查结果监测似乎没有必要。
- 作者认为,放弃频繁的实验室监测可以减少不必要的医疗支出,减轻患者因抽血产生的心理焦虑,并允许扩大这些有效口服药物的使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Terbinafine hydrochloride and griseofulvin are effective oral treatments for dermatophyte infections but have been associated with hepatic and hematologic abnormalities. The prevalence of alanine aminotransferase elevations, aspartate aminotransferase elevations, anemia, lymphopenia, and neutropenia among adults and children taking terbinafine and griseofulvin is unclear. OBJECTIVE: To measure the rate of laboratory test result abnormalities in healthy adults and children taking terbinafine or griseofulvin for dermatophyte infections. DESIGN, SETTING, AND PARTICIPANTS: This retrospective study assessed adults and children taking terbinafine or griseofulvin for dermatophyte infections from January 1, 2006, to December 31, 2016. Data were collected from one Midwest health care system. Exclusion criteria were preceding diagnosis of hepatic or hematologic condition and preceding or concurrent use of oral ketoconazole, amphotericin, or itraconazole. MAIN OUTCOMES AND MEASURES: The rates of elevated alanine aminotransferase measurements, elevated aspartate aminotransferase measurements, anemia, lymphopenia, and neutropenia in adults and children taking terbinafine, griseofulvin microsize, or griseofulvin ultramicrosize were calculated. Secondary measures included rates of baseline abnormalities, frequency of laboratory test results that required additional testing or discontinued use of medication, and laboratory test result monitoring practices. RESULTS: This study included laboratory data from 4985 patients (mean [SD] age, 42.8 [20.3] years; 2288 [45.9%] female) receiving 4309 courses of terbinafine, 634 courses of griseofulvin microsize, and 159 courses of griseofulvin ultramicrosize. We identified a low rate of laboratory test result abnormalities in patients taking terbinafine or griseofulvin. When laboratory test result abnormalities occurred, most were low grade (212 [93.4%] grade 1) and did not require subsequent laboratory test result evaluation or discontinued use of medication (15 051 [99.9%]). Elevations in alanine aminotransferase measurements were detected infrequently and were comparable to baseline detection rates (61 [3.5%] vs 95 [3.6%] for terbinafine, 2 [2.1%] vs 3 [3.7%] for griseofulvin microsize, and 0 vs 2 [5.0%] for griseofulvin ultramicrosize). Rates of elevated aspartate aminotransferase measurements, anemia, lymphopenia, and neutropenia were also infrequent and comparable to baseline rates. CONCLUSIONS AND RELEVANCE: In this study. the rates of alanine aminotransferase elevations, aspartate aminotransferase elevations, anemia, lymphopenia, and neutropenia in adults and children taking terbinafine or griseofulvin were low and equivalent to the baseline rates of abnormalities in this population. Routine interval laboratory test result monitoring appears to be unnecessary in adults and children without underlying hepatic or hematologic conditions taking terbinafine or griseofulvin for dermatophyte infections. Abandoning frequent laboratory monitoring can decrease unnecessary health care spending, decrease patient psychological angst associated with blood draws, and allow for expanded use of these effective oral medications.
引用
- Stolmeier DA, Stratman HB, McIntee TJ, et al. Utility of Laboratory Test Result Monitoring in Patients Taking Oral Terbinafine or Griseofulvin for Dermatophyte Infections. JAMA Dermatol. 2018. PMID: 30347032. doi:10.1001/jamadermatol.2018.3578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。